CAS: 1801765-04-7

TNO155 inhibits SHP2 enzyme with an IC50 of 0.011 μM, potentially aiding cancer treatment.

TNO155

TNO155 is an innovative therapeutic agent, commonly classified as a small-molecule inhibitor, which is derived from rational drug design based on precision oncology principles. Its mode of action involves selective inhibition of a specific protein tyrosine phosphatase, which plays a critical role in cellular signaling pathways that are often dysregulated in cancer. This inhibition effectively disrupts aberrant signaling, thereby suppressing tumor cell proliferation and inducing apoptosis in malignant cells. The primary applications of TNO155 are in the field of oncology, particularly for targeting tumors characterized by mutations that lead to unregulated signal transduction pathways. It holds potential for use in combination therapies, where it can enhance the efficacy of other chemotherapeutic agents by sensitizing cancer cells to treatment, or as a monotherapy in stratified patient populations defined by specific genetic biomarkers. Current research and clinical trials are exploring its efficacy across a range of solid tumors to fully delineate its therapeutic profile and utility in personalized medicine approaches.